A phase II study of hu14.18-IL2 [EMD 273063] in children with recurrent or refractory neuroblastoma
Phase of Trial: Phase II
Latest Information Update: 19 Feb 2015
At a glance
- Drugs Monoclonal antibody ch14 18 interleukin-2 fusion protein (Primary)
- Indications Neuroblastoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 02 Feb 2011 This study data provided drug development checkpoints to proceed to phase III in certain pediatric neuroblastoma subjects and Apeiron plans to continue clinical development in 2011, according to an Apeiron Biologics media release.
- 26 Mar 2008 Status changed from in progress to completed according to clinicaltrials.gov.